Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$677.00K$677.00K— vs Q2 2024 Net Income-$70.38M-$70.38MN/M vs Q2 2024 EPS Diluted-$0.41-$0.41N/M vs Q2 2024 Operating Income-$76,847,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$55,287,000N/M Margins · derivedOperating margin-11351.1%
Net margin-10395.1%
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end